IMMUNOGENICITY OF AN ACELLULAR PERTUSSIS VACCINE COMPOSED OF GENETICALLY INACTIVATED PERTUSSIS TOXIN COMBINED WITH FILAMENTOUS HEMAGGLUTININ AND PERTACTIN IN INFANTS AND CHILDREN

Antonio Cascio, Erminia Carapella^De Luca, Samuele Peppoloni, Rino Rappuoli, Audino Podda, Ilio Marsili, Marcella Bartalini, Anna Maria Casadei, Gianfranco Volpini, Lucina Titone, Luciano Nencioni, Antonio Cascio

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.
Original languageEnglish
Pages (from-to)81-84
Number of pages4
JournalJournal of Pediatrics
Volume123
Publication statusPublished - 1993

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'IMMUNOGENICITY OF AN ACELLULAR PERTUSSIS VACCINE COMPOSED OF GENETICALLY INACTIVATED PERTUSSIS TOXIN COMBINED WITH FILAMENTOUS HEMAGGLUTININ AND PERTACTIN IN INFANTS AND CHILDREN'. Together they form a unique fingerprint.

Cite this